

Accepted Manuscript

Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis

Andrea Manterola, Ana Bernal-Chico, Raffaella Cipriani, Asier Ruiz, Alberto Pérez-Samartín, Marta Moreno-Rodríguez, Ku-Lung Hsu, Benjamin Cravatt, J. Mark Brown, Rafael Rodríguez-Puertas, Carlos Matute, Susana Mato

PII: S0028-3908(18)30597-5

DOI: [10.1016/j.neuropharm.2018.08.038](https://doi.org/10.1016/j.neuropharm.2018.08.038)

Reference: NP 7323

To appear in: *Neuropharmacology*


Received Date: 8 February 2018

Revised Date: 30 July 2018

Accepted Date: 28 August 2018

Please cite this article as: Manterola, A., Bernal-Chico, A., Cipriani, R., Ruiz, A., Pérez-Samartín, A., Moreno-Rodríguez, M., Hsu, K.-L., Cravatt, B., Brown, J.M., Rodríguez-Puertas, R., Matute, C., Mato, S., Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis, *Neuropharmacology* (2018), doi: 10.1016/j.neuropharm.2018.08.038.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Re-examining the potential of targeting ABHD6 in multiple sclerosis: efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis

Andrea Manterola^{a,b,c}, Ana Bernal-Chico^{a,b,c†}, Raffaella Cipriani^{a,b}, Asier Ruiz^{a,b,c}, Alberto Pérez-Samartín^{a,b,c}, Marta Moreno-Rodríguez^d, Ku-Lung Hsu^e, Benjamin Cravatt^f, J Mark Brown^g, Rafael Rodríguez-Puertas^d, Carlos Matute^{a,b,c*} and Susana Mato^{a,b,c*}

^aDepartment of Neurosciences, University of the Basque Country UPV/EHU, 48940 Leioa, Spain

^bAchucarro Basque Center for Neuroscience, 48940 Leioa, Spain

^cCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain

^dDepartment of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain

^eDepartment of Chemistry, University of Virginia, 22904 Charlottesville, USA

^fDepartment of Chemical Physiology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 92037 La Jolla, USA

^gDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, 44195 Cleveland, USA

[†]Present address: Momentum Laboratory of Molecular Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary

*These authors jointly supervised this work

Corresponding author:

E-mail: susana.mato@ehu.es (S Mato)

E-mail: carlos.matute@ehu.es (C Matute)

Download English Version:

<https://daneshyari.com/en/article/10137413>

Download Persian Version:

<https://daneshyari.com/article/10137413>

[Daneshyari.com](https://daneshyari.com)